Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Angelo Antonini
Distinct subthalamic and pallidal beta dynamics in Parkinson’s disease
Abstract Despite the clinical use as a Deep Brain Stimulation (DBS) target in Parkinson’s disease (PD) and recent approval for adaptive stimulation, beta dynamics in the Globus Pallidus internus (GPi) remain poorly defined compared to the Subthalamic Nucleus (STN).
Early functional neuroimaging alterations in pTau217 biomarker-positive older adults
Abstract Introduction: Early identification of individuals with Alzheimer’s Disease (AD) is key to its successful management. In this regard, plasma biomarkers and functional magnetic resonance imaging alterations could represent useful triage tools for preclinical AD cases. Methods: In this study, we analyzed the relationship between neuroimaging, biological and cognitive data from 88 elderly participants recruited from the University Hospital of Padua.
Advance care planning and care coordination for people with parkinsonism: a randomized controlled trial
|
Abstract Parkinsonism comprises a group of progressive neurodegenerative disorders, including Parkinson’s disease and atypical parkinsonism. In advanced stages, advance care planning (ACP) and coordinated care are important to align treatment with patients’ values and reduce unwanted interventions and caregiver burden. In this study we evaluated whether a nurse-led intervention increases documentation of end-of-life preferences and improves patient and caregiver outcomes.
By Bauke W. Dijkstra, Michela Garon, Kristina Rosqvist, Monica Scharfenort, Laura Grover, Pille Taba, Anette Schrag, Spyridon Konitsiotis, Stefan Lorenzl, Per Odin, David Pedrosa, Kris C. P. Vissers, Marieke Groot, Bastiaan R Bloem, Marjan J. Meinders, Angelo Antonini, Catharina Muente, Katharina M. Lex, Eirini Nixina, Ülle Krikmann, Katrin Sikk, Philip Poku, Miltiadis Makrydimas
|
Nature
Verified
Parkinson disease therapy: current strategies and future research priorities
Abstract Parkinson disease (PD) is the fastest growing neurological disorder globally and poses substantial management challenges owing to progressive disability, emergence of levodopa-resistant symptoms, and treatment-related complications. In this Review, we examine the current state of research into PD therapies and outline future priorities for advancing our understanding and treatment of the disease.
Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease - npj Parkinson's Disease
Abstract The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson’s disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively.
No evidence for an association of voxel-based morphometry with short-term non-motor outcomes in deep brain stimulation for Parkinson’s disease - npj Parkinson's Disease
Abstract Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established therapy in advanced Parkinson’s disease (PD). Motor and non-motor outcomes, however, show considerable inter-individual variability. Preoperative morphometry-based metrics have recently received increasing attention to explain treatment effects.
Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
Article Dans Une Revue Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring Année : 2019 Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System Mots clés Biomarker Trials PSP MSA CBD CBS Neurodegeneration Biomarker Multicentric Multisite Neuroimaging Harmonization PET MRI Biomarker Trials PSP MSA CBD CBS Neurodegeneration Multicentric Multisite Neuroimaging Harmonization PET MRI Fichier principal Alz...
New Levodopa Infusion Systems for Advanced Parkinson’s Disease
Parkinson's Disease Read Time: 6 mins Copy Link Published Online: Jan 26th 2024 touchREVIEWS in Neurology. 2024;20(1):1–3:Online ahead of journal publication Authors: Angelo Antonini, Valentina D'Onofrio, Andrea Guerra Quick Links: Overview Advanced Parkinson’s disease is defined as a condition where periods of poor mobility with or without dyskinesia are present and have an impact on the functional independence of the affected person.
Exploring depression in Parkinson’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management
Neurological Sciences, Apr 2023 This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007/s10072-023-06740-w.pdf Stocchi, Fabrizio, Angelo Antonini, Barone, Paolo, Bellelli, Giuseppe, Fagiolini, Andrea, Ferini Strambi, Luigi, Sorbi, Sandro, Padovani, Alessandro. , Neurological Sciences, 2023, pp. 1-9, DOI: 10.1007/s10072-023-06740-w
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei - npj Parkinson's Disease
Abstract Neurological manifestations are common in COVID-19, the disease caused by SARS-CoV-2. Despite reports of SARS-CoV-2 detection in the brain and cerebrospinal fluid of COVID-19 patients, it is still unclear whether the virus can infect the central nervous system, and which neuropathological alterations can be ascribed to viral tropism, rather than immune-mediated mechanisms.
Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose Adjustment
To further clarify the role of opicapone in the optimisation of levodopa, the ADOPTION trial26 is an ongoing Phase IV, randomised, open-label, exploratory trial being conducted in 25 European sites.
Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus - npj Parkinson's Disease
Abstract Safinamide is a highly selective, reversible MAO B-inhibitor recently marketed in European and North American countries.
Patient-centred management of Parkinson's disease
The Personal View by Bloem and colleagues on integrated and patient-centred management of Parkinson's disease proposes a health system organisation to address complex care in chronic neurological disorders, using Parkinson's disease as an example. The proposed hub-and-spoke model envisions the integration of health professionals based on a Parkinson's disease centre of excellence integrated with community hospitals.
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease
Research Article Angelo Antonini MD Corresponding Author E-mail address: angelo3000@yahoo.com Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy Parkinson Institute, Via Bignami, 1, I‐20126 Milan, Italy Search for more papers by this author Abstract We performed a multicenter survey using a semistructured interview in 1,072 consecutive patients with Parkinson's disease (PD) enrolled during 12 months in 55 Italian centers to assess the prevalence of nonmotor symptoms...
Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE
Practice points Application of simple criteria to identify advanced Parkinson’s disease (PD) is important because early identification of advanced PD allows doctors to adjust treatment, leading to better symptom control and improved quality of life.
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
Abstract This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus on Parkinson’s disease.
Health care for chronic neurological patients after COVID-19
The ongoing spread of the coronavirus disease 2019 (COVID-19) pandemic is providing an opportunity to reassess and reconsider priorities in health-care systems. In the past two decades, high-income countries have developed the perception that we need to partly shift resources to chronic conditions and limit the number of hospital beds to admit only medical emergencies.
Outcome of Parkinson's Disease patients affected by COVID‐19
Letters: New Observations Valentina Leta MD King's College London, Department of neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, SE5 8AF United Kingdom Parkinson's Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, SE5 9RS United Kingdom Search for more papers by this author James Teo PhD King's College London, Department of neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London,...
New routes of dopaminergic drug delivery in patients with Parkinson's disease
Motor fluctuations represent a therapeutic challenge in the management of Parkinson's disease. They occur as a consequence of a combination of factors, including chronic pulsatile oral levodopa treatment, progressive loss of nigrostriatal nerve terminals, and reduced endogenous dopamine storage and release capacity. As mobility becomes progressively dependent on peripheral levodopa bioavailability, physicians need to adjust medications to preserve functionality and independence.
Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
1. Introduction Parkinsonian disorders are the most common neurodegenerative diseases after Alzheimer's disease [1x[1]Elbaz, A., Carcaillon, L., Kab, S., and Moisan, F. Epidemiology of Parkinson's disease. Rev Neurol (paris). 2016; 172: 14–26 Google ScholarSee all References][1].
Request Username Can't sign in? Forgot your username? Enter your email address below and we will send you your username If the address matches an existing account you will receive an email with instructions to retrieve your username
Request Username Can't sign in? Forgot your username? Enter your email address below and we will send you your username If the address matches an existing account you will receive an email with instructions to retrieve your username
Request Username Can't sign in? Forgot your username? Enter your email address below and we will send you your username If the address matches an existing account you will receive an email with instructions to retrieve your username
Apomorphine infusion in advanced Parkinson disease
The TOLEDO study provides new evidence to support the use of subcutaneous apomorphine infusion to control motor fluctuations in patients with advanced Parkinson disease. The findings should encourage neurologists to consider implementing apomorphine infusion or other device-aided therapies earlier in the disease course, before the emergence of troublesome dyskinesias.
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
The third principle in Box 1 is that an OM is of particular value if it separates “controlled” from “uncontrolled” symptoms and this value constitutes a therapeutic target (i.e., intervention should aim to move the patient toward the controlled state or “normal range”).8 In PD, the therapeutic target is often insufficiently defined and may vary over the course of the disease.
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease
This study was supported by AbbVie Inc., North Chicago, IL, USA. A Antonini was a study investigator and has received compensation for consultancy and speaker-related activities from UCG, Boston Scientific, Boehringer Ingelheim, AbbVie and Zambon. He has received research support from Mundipharma. WZ Robieson and L Bergmann are employees of AbbVie and may hold AbbVie stock and/or stock options. A Yegin was an employee of AbbVie at the time of the study; she is currently employed at Biogen.
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease
Aim: To determine if age and Parkinson's disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of daily living. Patients & methods: This post hoc analysis assessed subgroups of patients stratified by baseline age, disease duration, hours/day of ‘off’ time and levodopa equivalent dose. Patients’ data were collected from the GLORIA study, a 24-month observational registry evaluating long-term effectiveness of LCIG.
“Gunslinger’s gait”: a new cause of unilaterally reduced arm swing
Research “Gunslinger’s gait”: a...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Angelo
Contact Angelo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack